UPDATE: Barclays Downgrades United Therapeutics Corp. (UTHR) to Underweight
- Euro and global stocks hold Italy-related gains ahead of ECB
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
- GoDaddy (GDDY) to Acquire Host Europe Group in ~$1.8B Deal
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Trump's corporate tax holiday could spur pharma M&A
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - November 29, 2016 8:19 AM EST)
Barclays downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Equalweight to Underweight with a price target of $100.00 (from $115.00). Analyst Geoff Meacham said Orenitram uptake will likely be hindered due to Uptravi.
Shares of United Therapeutics Corp. closed at $132.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Goldman Sachs Downgrades Marvell (MRVL) to Sell
- Oppenheimer Raises Price Target on Itron (ITRI) to $70; Reiterates Outperform
- Barclays Upgrades Synovus Financial (SNV) to Equalweight
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!